Association between thrombolytic treatment and the prognosis of hemodynamically stable patients with major pulmonary embolism: Results of a multicenter registry

Circulation

Volumn 96, Issue 3, 1997, Pages 882-888

  Konstantinides, Stavros ^a,b   Geibel, Annette ^a   Olschewski, Manfred ^c   Heinrich, Fritz ^c   Grosser, Klaus ^c   Rauber, Klaus ^c   Iversen, Stein ^c   Redecker, Matthias ^a   Kienast, Joachim ^c   Just, Hanjörg ^a   Kasper, Wolfgang ^c  

^a Abteilung Innere Med III   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c NONE

Author keywords

Echocardiography; Embolism; Mortality; Prognosis; Thrombolysis

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT; HEMOGLOBIN; HEPARIN; STREPTOKINASE; UROKINASE; WARFARIN;

ADULT; AGED; ARTICLE; BLEEDING; BLOOD GAS ANALYSIS; ECHOCARDIOGRAPHY; FEMALE; FIBRINOLYTIC THERAPY; HEART CATHETERIZATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG ANGIOGRAPHY; LUNG EMBOLISM; LUNG SCINTISCANNING; MAJOR CLINICAL STUDY; MALE; MORTALITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROGNOSIS; STROKE; THROMBOSIS;

EID: 0030742062     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.96.3.882     Document Type: Article

References (20)

1. Stein PD, Hull RD, Raskob G. Risks for major bleeding from thrombolytic therapy in patients with acute pulmonary embolism. Ann Intern Med. 1994;121:313-317.
2. Hirsh J, Gale GS, McDonald IG, McCarthy RA, Pitt A. Streptokinase therapy in acute major pulmonary embolism: effectiveness and problems. Br Med J. 1968;4:729-734.
3. Miller AH, Sutton GC, Kerr IH, Gibson RV, Honey M. Comparison of streptokinase and heparin in treatment of isolated acute massive pulmonary embolism. Br Med J. 1971;2:681-684.
4. Goldhaber SZ, Vaughan DE, Markis JE, Selwyn AP, Meyerovitz MF, Loscalzo J, Soo Kim D, Kessler CM, Dawley DL, Sharma GVRK, Sasahara A, Grossbard EB, Braunwald E. Acute pulmonary embolism treated with tissue plasminogen activator. Lancet. 1986;2:886-889.
5. Dalla-Volta S, Palla A, Santolicandro A, Giuntini C, Pengo V, Visioli O, Zonzin P, Zanuttini D, Barbaresi F, Agnelli G, Morpurgo M, Marini MG, Visani L. PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism: Plasminogen Activator Italian Multicenter Study 2.J Am Coll Cardiol. 1992;20:520-526.
6. Goldhaber SZ, Haire WD, Feldstein ML, Miller M, Toltzis R, Smith JL, Taveira da Silva AM, Come PC, Lee RT, Parker JA, Mogtader A, McDonough TJ, Braunwald E. Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion. Lancet. 1993;341:507-511.
7. Goldhaber SZ. Pulmonary embolism thrombolysis: a clarion call for international collaboration. J Am Coll Cardiol. 1992;19:246-247.
8. Verstraete M. Thrombolytic treatment. Br Med J. 1995;311:582-583.
9. Meyer G, Sors H, Charbonnier B, Kasper W, Bassand JP, Kerr IH, Lesaffre E, Vanhove P, Verstraete M. Effect of intravenous urokinase versus alteplase on total pulmonary resistance in acute massive pulmonary embolism: a European multicenter double-blind trial. J Am Coll Cardiol. 1992;19:239-245.
10. Konstantinides S, Geibel A, Kasper W, Olschewski M, Kienast J, Iversen S, Grosser KD. Predictors of in-hospital mortality in patients with acute massive pulmonary embolism: results of the Management and Prognosis of Pulmonary Embolism Registry. Circulation. 1996;94(suppl I):I-572. Abstract.
11. Konstantinides S, Kasper W, Kienast J, Geibel A, Olschewski M, Redecker M, Rauber K, Heinrich F. Favorable effect of thrombolytic treatment on the clinical outcome of hemodynamically stable patients with acute massive pulmonary embolism. Circulation. 1996;94(suppl I):I-572. Abstract.
12. Kasper W, Geibel A, Tiede N, Bassenge D, Kauder E, Konstantinides S, Meinertz T, Just H. Distinguishing between acute and subacute massive pulmonary embolism by conventional and Doppler echocardiography. Br Heart J. 1993;70:352-356.
13. The Urokinase Pulmonary Embolism Trial Study Group. The Urokinase Pulmonary Embolism Trial: a national cooperative study. Circulation. 1973;47(suppl II):II-1-II-108.
14. Dalen JE, Banas JS, Brooks HL, Evans GL, Paraskos JA, Dexter L. Resolution rate of acute pulmonary embolism in man. N Engl J Med. 1969;280:1194-1199.
15. Jardin F, Dubourg O, Guéret P, Delorme G, Bourdarias JP. Quantitative two-dimensional echocardiography in massive pulmonary embolism: emphasis on ventricular interdependence and leftward septal displacement. J Am Coll Cardiol. 1987;10:1201-1206.
16. Jerjes-Sanchez C, Ramírez-Rivera A, de Lourdes Garcia M, Arriaga-Nava R, Valencia S, Rosado-Buzzo A, Pierzo JA, Rosas E. Streptokinase and heparin versus heparin alone in massive pulmonary embolism: a randomized controlled trial. J Thromb Thrombolys. 1995;2:227-229.
17. Alpert JS, Smith R, Carlson J, Ockene IS, Dexter L, Dalen JE. Mortality in patients treated for pulmonary embolism. JAMA. 1976; 236:1477-1480.
18. Carson JL, Kelley MA, Duff A, Weg JG, Fulkerson WJ, Palevsky HI, Schwartz S, Thompson BT, Popovich J, Hobbins TE, Spera MA, Alavi A, Terrin ML. The clinical course of pulmonary embolism. N Engl J Med. 1992;326:1240-1245.
19. Hull RD, Raskob GE, Coates G, Panju AA, Gill GJ. A new noninvasive management strategy for patients with suspected pulmonary embolism. Arch Intern Med. 1989;149:2549-2555.
20. Goldhaber SZ, Kessler CM, Heit J, Markis J, Sharma GV, Dawley D, Nagel JS, Meyerovitz M, Kim D, Vaughan DE, Parker JA, Tumeh S, Drum D, Loscalzo J, Reagan K, Selwyn AP, Anderson J, Braunwald E. Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism. Lancet. 1988;2:293-298.